Mucosal leishmaniasis . Current scenario and prospects for treatment.
about
The Dialogue of the Host-Parasite Relationship: Leishmania spp. and Trypanosoma cruzi InfectionMucosal leishmaniasis: an underestimated presentation of a neglected diseaseAdvances in Development of New Treatment for LeishmaniasisHIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensisDiagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Lack of Clinical Pharmacokinetic Studies to Optimize the Treatment of Neglected Tropical Diseases: A Systematic ReviewCutaneous Manifestations of Human and Murine LeishmaniasisMucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis in the Brazilian Amazon.Facial structure alterations and abnormalities of the paranasal sinuses on multidetector computed tomography scans of patients with treated mucosal leishmaniasis.Cutaneous leishmaniasis in Cuban immigrants to Texas who traveled through the Darién Jungle, PanamaMucosal leishmaniasis and abnormalities on computed tomographic scans of paranasal sinusesPterocarpanquinone LQB-118 induces apoptosis in Leishmania (Viannia) braziliensis and controls lesions in infected hamsters.Forecasting temporal dynamics of cutaneous leishmaniasis in Northeast Brazil.Oral manifestations in the American tegumentary leishmaniasis.Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update.A cluster of cutaneous leishmaniasis associated with human smugglingMyD88 and TLR9 dependent immune responses mediate resistance to Leishmania guyanensis infections, irrespective of Leishmania RNA virus burdenBioactivity Evaluation of Plant Extracts Used in Indigenous Medicine against the Snail, Biomphalaria glabrata, and the Larvae of Aedes aegypti.Leishmaniasis in the United States: treatment in 2012Differential Gene Expression and Infection Profiles of Cutaneous and Mucosal Leishmania braziliensis Isolates from the Same Patient.Further Evidence of an Association between the Presence of Leishmania RNA Virus 1 and the Mucosal Manifestations in Tegumentary Leishmaniasis Patients.Lip leishmaniasis: a case series with molecular identification and literature review.Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Mucosal Leishmaniasis from the New World: A Retrospective StudyAssociation of the Endobiont Double-Stranded RNA Virus LRV1 With Treatment Failure for Human Leishmaniasis Caused by Leishmania braziliensis in Peru and Bolivia.Association between an emerging disseminated form of leishmaniasis and Leishmania (Viannia) braziliensis strain polymorphisms.Toll-like receptors and leishmaniasis.Severe Cutaneous Leishmaniasis in a Human Immunodeficiency Virus Patient Coinfected with Leishmania braziliensis and Its Endosymbiotic Virus.Cutaneous leishmaniasis: disease susceptibility and pharmacogenetic implications.Treatment of cutaneous leishmaniasis in travelers 2009.Toll-like receptors in leishmania infections: guardians or promoters?Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis.LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014.Leishmania cell wall as a potent target for antiparasitic drugs. A focus on the glycoconjugates.Chemical Characterization, Antileishmanial Activity, and Cytotoxicity Effects of the Essential Oil from Leaves of Pluchea carolinensis (Jacq.) G. Don. (Asteraceae).The Role of Natural Products in Drug Discovery and Development against Neglected Tropical Diseases.Enhanced photodynamic leishmanicidal activity of hydrophobic zinc phthalocyanine within archaeolipids containing liposomesAn unclear, chronic nasal ulcer.Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis.American tegumentary leishmaniasis: T-cell differentiation profile of cutaneous and mucosal forms-co-infection with Trypanosoma cruzi.Oral effectiveness of PMIC4, a novel hydroxyethylpiperazine analogue, in Leishmania amazonensis
P2860
Q26829884-A2E1073E-468C-4671-96E3-69F41B4153D5Q26998036-A7CD3D2A-6480-4E04-B3AB-A9CE205CB449Q28082097-776880B3-A2DB-4549-B69F-4D0775B03FB4Q28475092-CE84E7DD-0001-4EDE-8119-75D70B4255D7Q30275257-65CB7BE6-266B-4ED8-8F4E-E8BF7E5EA4A1Q33658786-C23DB66A-C400-49BA-89E9-6B14355754E8Q33839048-0070C94C-B425-4023-9F78-B19F1A28762AQ33847397-E499A64B-B1DB-467C-B158-7A6980130DBAQ33981782-3A73A20C-FB89-4AA6-B712-7F21B213D4B0Q34015961-C424B3FC-6A02-48F1-8A54-9334FF2979A1Q34087321-D5EF288C-DA48-4494-9800-0B0FA72A0D32Q34395049-9E894F52-4B4E-4937-B093-053B5C68EAE1Q34428179-772AB7FA-D76C-4B09-8B8C-1A83A3370487Q34489065-9CA3824E-972E-4249-964D-6A87A1CA53AAQ34700686-B486DD8D-FB3B-4845-A057-97B6F5BA1849Q35031892-202C65E5-E935-4A98-8CBC-CC36CA1A548FQ35163825-90EAC1C7-CB5F-4968-9314-9A22E93616C4Q35615409-6CB98C82-0868-45F4-9D28-B2732A53157BQ35771790-C896FD83-0D76-4ED5-8907-CB7522DBCF7FQ35772188-31CECCFA-7B48-4CDA-9315-04AFA2589E34Q35776088-7D96571B-54B9-4A92-A130-45C6E2039B49Q36260068-A7B7E49F-DE7F-4F88-8A3D-485A6AFD31E2Q36359258-896663E6-19F8-46CE-9188-24FF1D9947D5Q36365284-9E895D90-539A-4274-98E4-E39146CCCCFEQ36414186-7C8418DF-A906-48AE-B3EE-D2C55B5B09ABQ36483521-20B4A7E3-9E7E-4618-AA33-1AAE6D21A3E0Q36776096-40B66E20-BAA6-4DF6-9B0E-FBD43EDF7DDBQ37416125-5D717D12-2097-42AD-A90C-523CFF6D9F43Q37428084-FA927988-99D3-4ECB-A081-A00AFBAF7190Q38004493-580A7FE4-DCEA-487B-B53B-313FC2BF9476Q38136837-75BA838E-27DE-4B44-AAC6-3507541FAF6BQ38205451-CD9C160F-9B0C-4F5E-BBBA-CF2BDEC43AA3Q38541158-6220668A-1DAC-4C72-A419-AA62B5831BD2Q38658307-22ACD1B8-CCF2-4C6B-802D-1C839FCFB088Q38943630-B8D12976-6ACD-48A2-AD6F-F3A554760737Q38973386-054331A5-1D15-431A-96C8-D80A6C87EE2BQ39507100-203BC8D2-06C6-4407-A944-50B5CA8EE186Q40235552-C4C21C59-253E-42E4-9684-4A9033CF70E4Q40730200-BBDFC947-D99D-468E-84AC-514132CDDAE5Q41595098-C98ED9A4-18F0-44C7-A723-D4CEEAF24D48
P2860
Mucosal leishmaniasis . Current scenario and prospects for treatment.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Mucosal leishmaniasis . Current scenario and prospects for treatment.
@en
type
label
Mucosal leishmaniasis . Current scenario and prospects for treatment.
@en
prefLabel
Mucosal leishmaniasis . Current scenario and prospects for treatment.
@en
P2093
P1433
P1476
Mucosal leishmaniasis . Current scenario and prospects for treatment
@en
P2093
Antonio Carlos Nicodemo
Hélio Arthur Bacha
Valdir Sabbaga Amato
Vicente Amato Neto
P356
10.1016/J.ACTATROPICA.2007.08.003
P577
2007-08-19T00:00:00Z